Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.
Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa. A clinical study was conducted on forty hospitalized patients with bacteriologically proven urinary tract infections; 20 patients were given norfloxacin and 20 co-trimoxazole. Clinical results were excellent in both groups; norfloxacin was effective in infections due to Ps. aeruginosa and other multi-resistant pathogens. No side effects were reported.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009268:Nalidixic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009643:Norfloxacin; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000890:Anti-Infective Agents; D009268:Nalidixic Acid; D009643:Norfloxacin